Stockreport

Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

Longeveron Inc. - Class A Common stock  (LGVN) 
PDF Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C meeting with U.S. FDA confir [Read more]